Please login to the form below

Not currently logged in
Email:
Password:

Oncaspar

This page shows the latest Oncaspar news and features for those working in and with pharma, biotech and healthcare.

Half of European cancer drug trials ‘biased’, says BMJ

Half of European cancer drug trials ‘biased’, says BMJ

That included Servier’s leukaemia treatment Oncaspar(pegaspargase), which had five studies deemed to be at risk, while others included Novartis’  Mekinist(trametinib; three studies) and Pfizer’s  Ibrance(palbociclib; two

Latest news

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    1, 100. Sigma Tau/ Baxter. Asset acquisition. Oncaspar (pegasparagase - marketed) portfolio in acute lymphoblastic leukaemia (ALL).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics